Immunopharmacology Comments

Tregalizumab was designed to selectively activate Treg cells and boost their function to mediate an increase in their immunosuppressive activity [1-2].

Immunopharmacology Disease
Disease	X-Refs	Comment	References
Rheumatoid arthritis	Disease Ontology: DOID:7148 OMIM: 180300	Tregalizumab failed to show clinical efficacy in Phase 2 trial (NCT01999192), and development was discontinued.	3